Comments
Serum Institute Chief Executive Adar Poonawalla on Sunday that all the risks that SII took for stockpiling the Covidshield vaccine for Covid-19 has worked after India approved the vaccine for emergency use.
“Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paidoff. COVISHIELD, India's first COVID-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks,” Poonawalla said in a tweet.
The Indian drug regulator on Sunday approved the AstraZeneca-Oxford University Covid-19 vaccine along with theindigenous vaccine developed by Bharat Biotech developed together with the Indian Council of Medical Research (ICMR) labs.
Related Stories
Serum Institute to have 100 million doses of vaccine by early January
The Pune firm is yet to get emergency use approval in IndiaThe final approval was given by the Central Drugs Standard Control Organisation (CDSCO) on the basis of the recommendationsgiven by the Subject Expert Committee (SEC) on Saturday.
SII produces and markets the approved AstraZeneca-Oxford University vaccine under the name Covishield. SII hadsaid that it will have a stockpile of 100 million doses by the first week of January, as per previous reports.
India plans to inoculate 30 crore people in the first phase of vaccination.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.